




Patent Docket P17261PI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Leonard Presta Serial No.: 09/713,425 Filed: November 15, 2000 For: POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION	Group Art Unit: 1653 Examiner: To Be Assigned CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on March 13, 2001  Anna Kan
---	--

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37

CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) are not supplied.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-()" (nucleotide) and "BLAST Results B-1 - B-()" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

- [] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Date: March 1, 2001

By: _____

Wendy M. Lee

Reg. No. 40,378

Telephone No. (650) 225-1994



09157

PATENT TRADEMARK OFFICE

FORM PTO 449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09/713,425

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Presta, L.

Filing Date

15 Nov 2000

Group
1653

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
	1 4,752,601	21.06.88	Hahn			
	2 5,348,876	20.09.94	Michaelson et al.			
	3 5,624,821	29.04.97	Winter et al.			
	4 5,648,260	15.07.97	Winter et al.			
	5 5,698,449	15.12.97	Baumann et al.			
	6 5,736,137	07.04.98	Anderson et al.			
	7 5,935,599	15.11.99	McKenzie et al.			
	8 6,194,551 B1	27.02.01	Idusogie et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	9 WO 00/09560	04.02.00	PCT				
	10 WO 88/07089	02.09.88	PCT				
	11 WO 94/29351	02.12.94	PCT				
	12 WO 97/28267	07.08.97	PCT				
	13 WO 97/44362	27.11.97	PCT				
	14 WO 98/23289	04.06.98	PCT				
	15 WO 98/52975	26.11.98	PCT				
	16 WO 99/43713	02.09.99	PCT				
	17 WO 99/51642	14.10.99	PCT				
	18 WO 99/58572	18.11.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

19	Allan and Isliker, "Studies on the complement-binding site of rabbit immunoglobulin G-I. Modification of tryptophan residues and their role in anticomplementary activity of rabbit IgG" <u>Immunochemistry</u> 11(4):175-180 (Apr 1974)
20	Angal et al., "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody" <u>Molecular Immunology</u> 30(1):105-108 (Jan 1993)
21	Armour et al., "Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities" <u>European Journal of Immunology</u> 29(8):2613-2624 (Aug 1999)
22	Bloom et al., "Intrachain disulfide bond in the core hinge region of human IgG4" <u>Protein Science</u> 6:407-415 (1997)
23	Bolland et al., "SHIP modulates immune receptor responses by regulating membrane association of Btk" <u>Immunity</u> 8(4):509-516 (Apr 1998)
24	Bredius et al., "Role of neutrophil FcγRIIa (CD32) and FcγRIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes" <u>Immunology</u> 83(4):624-630 (Dec 1994)
25	Brekke et al., "Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis" <u>European Journal of Immunology</u> 24(10):2542-2547 (Oct 1994)
26	Burmeister et al., "Crystal structure of the complex of rat neonatal Fc receptor with Fc" <u>Nature</u> 372(6504):379-383 (Nov 24, 1994)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09/713,025

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Presta, L.

Filing Date

15 Nov 2000

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

27	Burton and Woof, "Human Antibody Effector Function" <u>Advances in Immunology</u> 51:1-84 (1992)
28	Burton et al., "Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI)" <u>Molecular Immunology</u> 25(11):1175-1181 (1988)
29	Burton et al., "The Clq receptor site on immunoglobulin G" <u>Nature</u> 288(5789):338-344 (Nov 27, 1980)
30	Burton, D.R., "Immunoglobulin G: Functional Sites" <u>Molecular Immunology</u> 22(3):161-206 (1985)
31	Canfield and Morrison, "The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the C _H 2 domain and is modulated by the hinge region" <u>Journal of Experimental Medicine</u> 173(6):1483-1491 (Jun 1, 1991)
32	Capel et al., "Heterogeneity of Human IgG Fc Receptors" <u>Immunomethods</u> 4:25-34 (1994)
33	Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy" <u>Nature</u> 337:525-531 (February 9, 1989)
34	Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (1992)
35	Chappel et al., "Identification of Secondary FcγRI Binding Site within a Genetically Engineered Human IgG Antibody" <u>Journal of Biological Chemistry</u> 268:25124-25131 (1993)
36	Chappel et al., "Identification of the Fcγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 88(20):9036-9040 (Oct 15, 1991)
37	Clynes and Ravetch, "Cytotoxic antibodies trigger inflammation through Fc receptors" <u>Immunity</u> 3(1):21-26 (Jul 1995)
38	Clynes et al., "Fc receptors are required in passive and active immunity to melanoma" <u>Proc. Natl. Acad. Sci. USA</u> 95(2):652-656 (Jan 20, 1998)
39	Clynes et al., "Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors" <u>Journal of Experimental Medicine</u> 189(1):179-185 (Jan 4, 1999)
40	Clynes et al., "Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis" <u>Science</u> 279(5353):1052-1054 (Feb 13, 1998)
41	Cosimi, A.B., "Clinical Development of ORTHOCLONE OKT3" <u>Transplantation Proceedings</u> (Suppl 1) XIX(2):7-16 (Apr 1987)
42	Daeron, M., "Fc Receptor Biology" <u>Annual Review of Immunology</u> 15:203-234 (1997)
43	de Haas et al., "Fcγ receptors of phagocytes" <u>J. of Laboratory Clinical Medicine</u> 126:330-341 (1995)
44	Deisenhofer, J., "Crystallographic Refinement and Atomic Models of a Human Fc fragment and Its Complex with Fragment B of Protein A from Staphylococcus aureus at 2.9- and 2.8-Å Resolution" <u>Biochemistry</u> 20(9):2361-2370 (1981)
45	Duncan and Winter, "The binding site for Clq on IgG" <u>Nature</u> 332:738-740 (Apr 21, 1988)
46	Duncan et al., "Localization of the binding site for the human high-affinity FC receptor on IgG" <u>Nature</u> 332:563-564 (April 7, 1988)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

MAR 23 2001

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09/717,455

Applicant

Presta, L.

Filing Date

15 Nov 2000

Group

1653

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|----|--|
| 47 | Gazzano-Santoro et al., "A non-radioactive complement-dependent cytotoxicity assay for a CD20 monoclonal antibody" <u>Journal of Immunological Methods</u> 202:163-171 (1997) |
| 48 | Gergely et al., "Fc receptors on lymphocytes and K cells" <u>Biochemical Society Transactions</u> 12(5):739-743 (Oct 1984) |
| 49 | Ghebrehiwet et al., "Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q" <u>Journal of Experimental Medicine</u> 179(6):1809-1821 (Jun 1, 1994) |
| 50 | Ghetie and Ward, "FcRn: the MHC class I-related receptor that is more than an IgG transporter" <u>Immunology Today</u> 18(12):592-593 (Dec 1997) |
| 51 | Ghetie et al., "Abnormally short serum half-lives of IgG in β 2-microglobulin-deficient mice" <u>European Journal of Immunology</u> 26(3):690-696 (Mar 1996) |
| 52 | Ghetie et al., "Increasing the serum persistence of an IgG fragment by random mutagenesis" <u>Nature Biotechnology</u> 15(7):637-640 (Jul 1997) |
| 53 | Gorman et al., "Transient Production of Proteins Using an Adenovirus Transformed Cell Line" <u>DNA Prot. Eng. Tech.</u> 2(1):3-10 (1990) |
| 54 | Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-74 (1977) |
| 55 | Greenwood et al., "Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis" <u>Therapeutic Immunology</u> 1(5):247-255 (Oct 1994) |
| 56 | Greenwood et al., "Structural motifs involved in human IgG antibody effector functions" <u>European Journal of Immunology</u> 23(5):1098-1104 (May 1993) |
| 57 | Guddat et al., "Three-dimensional structure of a human immunoglobulin with a hinge deletion" <u>PNAS (USA)</u> 90:4271-4275 (1993) |
| 58 | Haagen et al., "Interaction of Human Monocyte Fc γ Receptors with Rat IgG2b: A New Indicator for the Fc γ RIIa (R-H131) Polymorphism" <u>J. Immunol.</u> 154:1852-1860 (1995) |
| 59 | Hadley et al., "The functional activity of Fc γ RII and Fc γ RIII on subsets of human lymphocytes" <u>Immunology</u> 75(3):446-451 (Jul 1992) |
| 60 | Harris et al., "Crystallographic Structure of an Intact IgG1 Monoclonal Antibody" <u>Journal of Molecular Biology</u> 275:361-872 (1998) |
| 61 | Harris et al., "Refined Structure of an Intact IgG2a Monoclonal Antibody" <u>Biochemistry</u> 36:1581-1597 (1997) |
| 62 | Hatta et al., "Association of Fc γ receptor IIIB, but not of Fc γ receptor IIA and IIIA, polymorphisms with systemic lupus erythematosus in Japanese" <u>Genes and Immunity</u> 1:53-60 (1999) |
| 63 | Heiken et al., "T lymphocyte development in the absence of Fc ϵ receptor I γ subunit: analysis of thymic-dependent and independent $\alpha\beta$ and $\gamma\delta$ pathways" <u>European Journal of Immunology</u> 26(8):1935-1943 (Aug 1996) |
| 64 | Henry et al., "Participation of the N-terminal region of C ϵ 3 in the binding of human IgE to its high-affinity receptor Fc ϵ RI" <u>Biochemistry</u> 36:15568-15578 (1997) |
| 65 | Hogarth et al., "Characterization of Fc ϵ Ig-binding sites and epitope mapping" <u>Immunomethods</u> 4(1):17-24 (Feb 1994) |
| 66 | Huizinga et al., "Binding Characteristics of Dimeric IgG Subclass Complexes to Human Neutrophils" <u>Journal of Immunology</u> 142:2359-2364 (1989) |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

MAR 23 2001

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

713,465

Applicant

Presta, L.

Filing Date

15 Nov 2000

Group

1

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

67	Hulett et al., "Chimeric Fc Receptors Identify Functional Domains of the Murine High Affinity Receptors for IgG" <u>J. Immunol.</u> 147:1863-1868 (1991)
68	Jaakkola et al., "In vivo detection of vascular adhesion protein-1 in experimental inflammation" <u>American Journal of Pathology</u> 157(2):463-471 (Aug 2000)
69	Janeway et al. <u>Immunobiology, The Immune System in Health and Disease</u> , CB Ltd and Garland Publishing Inc., NY & London (1994)
70	Jefferis et al., "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcγR)" <u>Molecular Immunology</u> 27(12):1237-1240 (1990)
* 71	<u>Fabat Sequences of Proteins of Immunological Interest</u> , US Dept of Health and Human Services, NIH, 5th edition, Bethesda, MD (1991)
72	Fabat, E. et al. <u>Sequences of Proteins of Immunological Interest</u> (pgs. 569, 671, 687, 696), 5th edition, Bethesda, MD:NIH Vol. 1 (1991)
73	Fim et al., "Catabolism of the Murine IgG1 Molecule Evidence That Both CH2-CH3 Domain Interfaces are Required for Persistence of IgG1 in the Circulation of Mice" <u>Scandinavian Journal Of Immunology</u> 40(4):457-465 (1994)
74	Fim et al., "Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis" <u>European Journal of Immunology</u> 24:542-548 (1994)
75	Fim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo" <u>Nature</u> 362:841-844 (1993)
76	Fim et al., "Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor" <u>European Journal of Immunology</u> 24:2429-2434 (1994)
77	Fim et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies" <u>Growth Factors</u> 7(1):53-64 (1992)
78	Koene et al., "FcγRIIIa-158V/F Polymorphism Influences the Binding of the IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype" <u>Blood</u> 90(3):1109-1114 (1997)
79	Kunkel, T., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection" <u>Proc. Natl. Acad. Sci.</u> 82:488-492 (1985)
80	Lauvrak et al., "Identification and characterisation of Clq-binding phage displayed peptides" <u>Biological Chemistry</u> 378(12):1509-1519 (Dec 1997)
81	Lehrnbecher et al., "Variant genotypes of FcγRIIIa influence the development of Kaposi's sarcoma in HIV-infected men" <u>Blood</u> 95(7):2386-2390 (2000)
82	Lehrnbecher et al., "Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations" <u>Blood</u> 94(12):4220-4232 (Dec 15, 1999)
83	Li et al., "Reconstitution of human FcγRIII cell type specificity in transgenic mice" <u>Journal of Experimental Medicine</u> 183(3):1259-1263 (Mar 1, 1996)
84	Lifely et al., "Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions" <u>Glycobiology</u> 5(8):813-822 (Dec 1995)
85	Lorenz et al., "Strong association between the responder status of the FcγII receptor and recurrent spontaneous abortion" <u>European Journal of Immunogenetics</u> 22(5):397-401 (Oct 1995)
86	Lucas et al., "High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector" <u>Nucleic Acids Research</u> 24(9):1774-1779 (1996)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 LIST OF DISCLOSURES PRESENTED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1726R1P1	Sheet 5 of 8 Serial No. 09/778,425
Applicant Presta, L.		Filing Date 15 Nov 2000		Group 165	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
87	Lund et al., "Human FcγRI and FcγRII interact with distinct but overlapping sites on human IgG" <u>Journal of Immunology</u> 147(8):2657-2662 (Oct 15, 1991)				
88	Lund et al., "Multiple binding sites on the CH2 domain of IgG for mouse FcγRII" <u>Molecular Immunology</u> 29(1):53-59 (Jan 1992)				
89	Lund et al., "Multiple Interactions of the IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fcγ Receptor I and Influence the Synthesis of Its Oligosaccharide Chains" <u>J. Immunol.</u> 157:4963-4969 (1996)				
90	Lund et al., "Oligosaccharide-protein interactions in IgG can modulate recognition by Fcγ receptors" <u>FASEB Journal</u> 9:115-119 (1995)				
91	Medesan et al., "Comparative studies of rat IgG to further delineate the Fc:FcRN interaction site" <u>European Journal of Immunology</u> 28:2092-2100 (1998)				
92	Medesan et al., "Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1" <u>Journal of Immunology</u> 158(5):2211-2217 (Mar 1, 1997)				
93	Medesan et al., "Localization of the site of the IgG molecule that regulates maternal-fetal transmission in mice" <u>European Journal of Immunology</u> 26(10):2533-2536 (Oct 1996)				
94	Meng et al., "Green fluorescent protein as a second selectable marker for selection of high producing clones from transfected CHO cells" <u>Gene</u> 242:201-207 (2000)				
95	Miller et al., "A Novel Role for the Fc Receptor γ Subunit: Enhancement of the FcγR Ligand Affinity" <u>Journal of Experimental Medicine</u> 183:2227-2233 (1996)				
96	Morgan et al., "The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcγRIII binding" <u>Immunology</u> 86(2):319-324 (Oct 1995)				
97	Morrison et al., "Structural Determinants of Human IgG Function" <u>Immunologist</u> 2:119-124 (1994)				
98	Nagarajan et al., "Ligand binding and phagocytosis by CD16 (Fc γ receptor III) isoforms. Phagocytic signaling by associated ζ and γ subunits in Chinese hamster ovary cells" <u>Journal of Biological Chemistry</u> 270(43):25762-25770 (Oct 27, 1995)				
99	Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox" <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz & Le Grand, Boston: Birkhauser pps. 491-495 (1994)				
100	Nieto et al., "Involvement of the Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis" <u>Arthritis and Rheumatism</u> 43(4):735-739 (2000)				
101	Okada et al., "Cutting Edge: Role of the inositol phosphatase SHIP in B cell receptor-induced Ca ²⁺ oscillatory response" <u>Journal of Immunology</u> 161(10):5129-5132 (Nov 15, 1998)				
102	Ono et al., "Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling" <u>Cell</u> 90(2):293-301 (Jul 25, 1997)				
103	Ono et al., "Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB" <u>Nature</u> 383(6597):263-266 (Sep 19, 1996)				
104	Papac et al., "A high-throughput microscale method to release N-linked oligosaccharide from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis" <u>Glycobiology</u> 8(5):445-454 (1998)				
105	Papac et al., "Analysis of Acidic Oligosaccharides and Glycopeptides by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry" <u>Anal. Chem.</u> 68:3215-3223 (1996)				
106	Popov et al., "The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn" <u>Molecular Immunology</u> 33(6):521-530 (Apr 1996)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09/703 125

Applicant

Presta, L.

Filing Date

15 Nov 2000

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

107	Porges et al., "Novel Fcγ Receptor I Family Gene Products in Human Mononuclear Cells" <u>J. Clin. Invest.</u> 90:2102-2109 (1992)
108	Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57(20):4593-4599 (Oct 15, 1997)
109	Raghavan and Bjorkman, "Fc Receptors and their Interactions with Immunoglobulins" <u>Annu. Rev. Cell. Dev. Biol.</u> 12:181-220 (1996)
110	Raghavan et al., "Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants" <u>Biochemistry</u> 34(45):14649-14657 (Nov 14, 1995)
111	Ravetch and Clynes, "Divergent roles for Fc receptors and complement in vivo" <u>Annual Review of Immunology</u> 16:421-432 (1998)
112	Ravetch and Kinet, "Fc Receptors" <u>Annual Review of Immunology</u> 9:457-492 (1991)
113	Ravetch, J., "Fc receptors" <u>Current Opinion in Immunology</u> 9(1):121-125 (Feb 1997)
114	Ravetch, J., "Fc receptors: rubor redux" <u>Cell</u> 78(4):553-560 (Aug 26, 1994)
115	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20" <u>Blood</u> 83(2):435-445 (Jan 15, 1994)
116	Sarmay et al., "Ligand inhibition studies on the role of Fc receptors in antibody-dependent cell-mediated cytotoxicity" <u>Molecular Immunology</u> 21(1):43-51 (Jan 1984)
117	Sarmay et al., "Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fcγ receptor" <u>Molecular Immunology</u> 29(5):633-639 (May 1992)
118	Sensel et al., "Amino acid differences in the N-terminus of Cγ2 influence the relative abilities of IgG2 and IgG3 to activate complement" <u>Molecular Immunology</u> 34(14):1019-1029 (Oct 1997)
119	Shores et al., "T cell development in mice lacking all T cell receptor ζ family members (ζ, η, and FcεRIγ)" <u>Journal of Experimental Medicine</u> 187(7):1093-1101 (Apr 6, 1998)
120	Sondermann et al., "Crystal structure of the soluble form of the human Fcγ-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution" <u>EMBO Journal</u> 18(5):1095-1103 (1999)
121	Sondermann et al., "The 32-A crystal structure of the human IgG1 Fc Fragment-FcγRIII complex" <u>Nature</u> 406:267-273 (2000)
122	Strohmeier et al., "Neutrophil functional responses depend on immune complex valency" <u>Journal of Leukocyte Biology</u> 58(4):403-414 (Oct 1995)
123	Strohmeier et al., "Role of the FcγR subclasses FcγRII and FcγRIII in the activation of human neutrophils by low and high valency immune complexes" <u>Journal of Leukocyte Biology</u> 58(4):415-422 (Oct 1995)
124	Suzuki et al., "Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis" <u>Kidney International</u> 54(4):1166-1174 (Oct 1998)
125	Sylvestre and Ravetch, "A dominant role for mast cell Fc receptors in the Arthus reaction" <u>Immunity</u> 5(4):387-390 (Oct 1996)
126	Sylvestre and Ravetch, "Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade" <u>Science</u> 265(5175):1095-1098 (Aug 19, 1994)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09,713,425

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Presta, L.

Filing Date

15 Nov 2000

Class

1653

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|-----|--|
| 127 | Sylvestre et al., "Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice" <u>Journal of Experimental Medicine</u> 184(6):2385-2392 (Aug 1, 1996) |
| 128 | Takai et al., "Augmented humoral and anaphylactic responses in FcγII-deficient mice" <u>Nature</u> 379(6563):346-349 (Jan 25, 1996) |
| 129 | Takai et al., "Fcγ chain deletion results in pleiotrophic effector cell defects" <u>Cell</u> 76(3):519-529 (Feb 11, 1994) |
| 130 | Tanm et al., "The IgG binding site of human FcγRIIIB receptor involves CC' and FG loops of the membrane-proximal domain" <u>Journal of Biological Chemistry</u> 271(7):3659-3666 (Feb 16, 1996) |
| 131 | Tao et al., "Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation" <u>Journal of Experimental Medicine</u> 178(2):661-667 (Aug 1, 1993) |
| 132 | Tao et al., "Studies of aglycosylated chimeric mouse-human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region" <u>Journal of Immunology</u> 143(8):2595-2601 (Oct 15, 1989) |
| 133 | Tao et al., "The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain" <u>Journal of Experimental Medicine</u> 173(4):1025-1028 (Apr 1991) |
| 134 | Tax et al., "Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody-induced T cell proliferation" <u>Journal of Immunology</u> 133(3):1185-1189 (Sep 1984) |
| 135 | Ting et al., "Fcγ receptor activation induces the tyrosine phosphorylation of both phospholipase C (PLC)-γ1 and PLC-γ2 in natural killer cells" <u>Journal of Experimental Medicine</u> 176(6):1751-1755 (Dec 1, 1992) |
| 136 | Umana et al., "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity" <u>Nature Biotechnology</u> 17:176-180 (1999) |
| 137 | Urfer et al., "High resolution mapping of the binding site of TrkA for nerve growth factor and TrkC for neurotrophin-3 on the second immunoglobulin-like domain of the Trk receptors" <u>Journal of Biological Chemistry</u> 273(10):5829-5840 (Mar 6, 1998) |
| 138 | Van de Winkel and Anderson, "Biology of human immunoglobulin G Fc receptors" <u>Journal of Leukocyte Biology</u> 49(5):511-524 (May 1991) |
| 139 | Vance et al., "Binding of monomeric human IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells" <u>Journal of Immunology</u> 151(11):6429-6439 (Dec 1, 1993) |
| 140 | Ward and Ghetie, "The effector functions of immunoglobulins: implications for therapy" <u>Therapeutic Immunology</u> 2(2):77-94 (1995) |
| 141 | Warmerdam et al., "A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding" <u>Journal of Immunology</u> 147(4):1338-1343 (Aug 15, 1991) |
| 142 | Weng et al., "Computational determination of the structure of rat Fc bound to the neonatal Fc receptor" <u>Journal of Molecular Biology</u> 282(2):217-225 (Sep 18, 1998) |
| 143 | Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <u>J. of Immunology</u> 157:4986-4995 (1996) |
| 144 | Woof et al., "Localisation of the monocyte-binding region on human immunoglobulin G" <u>Molecular Immunology</u> 23(3):319-330 (Mar 1986) |
| 145 | Wright and Morrison, "Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1" <u>Journal of Experimental Medicine</u> 180(3):1087-1096 (Sep 1, 1994) |
| 146 | Wu et al., "A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease" <u>Journal of Clinical Investigation</u> 100(5):1059-1070 (Sep 1, 1997) |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09713.425

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant:

Presta, L.

Filing Date

15 Nov 2000

Group

1653

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.